FIA
MBX

FNY Investment Advisers’s MBX Biosciences MBX Stock Holding History

FNY Investment Advisers’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,575
Closed -$27K – 1593
2025
Q3 		$27K Buy
+1,575
New +$21.1K 0.01% 632

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

FNY Investment Advisers's MBX Position: Q4 2025 in Review

FNY Investment Advisers sold out of MBX Biosciences (MBX) in Q4 2025, closing a stake of 1,575 shares — an estimated $27K sold.

FNY Investment Advisers first reported a position in MBX in Q3 2025 and held it in 1 quarter. The position peaked at $27K in Q3 2025. 138 funds tracked by Wall St. Rank hold MBX as of Q4 2025.

  • FNY Investment Advisers reported no remaining MBX Biosciences position as of Q4 2025 after selling out during the quarter.
  • FNY Investment Advisers sold 1,575 MBX Biosciences shares in Q4 2025, an estimated $27K.
  • FNY Investment Advisers first reported a position in MBX Biosciences in Q3 2025 and held it in 1 quarter.
  • FNY Investment Advisers's MBX Biosciences position peaked at $27K in Q3 2025.
  • 138 funds tracked by Wall St. Rank held MBX Biosciences as of Q4 2025.

Based on FNY Investment Advisers's 13F filing for Q4 2025, filed 16 Jan 2026.